HC Wainwright Issues Negative Estimate for HRMY Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Stock analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for shares of Harmony Biosciences in a research report issued to clients and investors on Wednesday, February 25th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of $0.76 per share for the quarter, down from their previous forecast of $0.86. HC Wainwright has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q2 2026 earnings at $0.92 EPS, Q3 2026 earnings at $1.09 EPS, Q4 2026 earnings at $1.31 EPS and FY2030 earnings at $7.07 EPS.

A number of other brokerages have also issued reports on HRMY. Weiss Ratings restated a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 29th. Zacks Research downgraded Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Needham & Company LLC lowered their price objective on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday. Oppenheimer reiterated an “outperform” rating and set a $62.00 target price on shares of Harmony Biosciences in a research report on Monday, November 24th. Finally, UBS Group decreased their price target on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $42.67.

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $28.54 on Friday. Harmony Biosciences has a 52 week low of $25.52 and a 52 week high of $40.87. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of 10.53, a P/E/G ratio of 0.36 and a beta of 0.84. The firm’s 50-day simple moving average is $36.01 and its 200 day simple moving average is $34.07. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.72 and a current ratio of 3.60.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.46). The firm had revenue of $243.78 million for the quarter, compared to the consensus estimate of $240.04 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The firm’s quarterly revenue was up 21.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.85 EPS.

Hedge Funds Weigh In On Harmony Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Robeco Institutional Asset Management B.V. grew its stake in shares of Harmony Biosciences by 0.6% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 47,085 shares of the company’s stock worth $1,762,000 after buying an additional 298 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Harmony Biosciences by 1.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 28,639 shares of the company’s stock valued at $789,000 after acquiring an additional 348 shares in the last quarter. Nebula Research & Development LLC boosted its holdings in shares of Harmony Biosciences by 2.0% during the 2nd quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock valued at $550,000 after acquiring an additional 348 shares in the last quarter. Amalgamated Bank grew its position in Harmony Biosciences by 3.8% during the 3rd quarter. Amalgamated Bank now owns 11,328 shares of the company’s stock worth $312,000 after acquiring an additional 417 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its holdings in Harmony Biosciences by 12.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,466 shares of the company’s stock worth $141,000 after purchasing an additional 479 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

Insider Buying and Selling at Harmony Biosciences

In other news, CFO Sandip Kapadia sold 3,746 shares of the stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $37.15, for a total value of $139,163.90. Following the completion of the transaction, the chief financial officer owned 24,521 shares of the company’s stock, valued at approximately $910,955.15. This represents a 13.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total transaction of $1,040,172.63. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 50,640 shares of company stock valued at $1,932,256. 23.60% of the stock is owned by corporate insiders.

Key Stories Impacting Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $55 price target and published a long-range FY2030 EPS projection (which reinforces an upbeat long-term thesis), supporting upside potential despite near-term cuts. HC Wainwright research on HRMY
• Neutral Sentiment: An aggregate coverage note reported HRMY has an average analyst rating of “Moderate Buy,” indicating mixed consensus sentiment across the sell-side. This tempers the impact of individual downgrades but leaves the stock sensitive to further model changes. Average analyst rating report
• Negative Sentiment: Zacks Research downgraded HRMY from “strong-buy” to “hold,” reducing near-term buy-side conviction and likely contributing to selling pressure. Zacks downgrade
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” citing patent trial developments — a direct legal/intellectual property risk that can materially affect exclusivity and future revenue, and is a key reason for today’s weakness. Truist downgrade after patent trial developments
• Negative Sentiment: HC Wainwright also lowered near-term EPS forecasts across Q1–Q4 2026 (multiple cuts to quarterly estimates), signaling weaker near-term profitability expectations that can pressure the stock until guidance or sales trends rebound. HC Wainwright EPS revision details

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.